Intrathecal Neostigmine Use For Postoperative Analgesia

• Main Authors: Tarkan Öztürk, Gönül Ölmez, Mehmet Ali Özyılmaz
• Format: Article
• Language: English
• Published: Dicle University Medical School 2003-03-01
• Series: Dicle Medical Journal
• Subjects: Acetylcholine; analgesia; cholinergic; nausea.
• Online Access: http://4181.indexcopernicus.com/fulltxt.php?ICID=888567
• ISSN: 1300-2945; 1308-9889

This study aims at evaluating postoperative analgesic efficacy and safety of intrathecal neostigmine doses in patients under hemispinal anesthesia. After Ethics Committee approval, 48 patients sheduled for elective arthroscopic surgery.patients were randomly divided into four groups. Hemispinal block technique was performed at the lateral decubitis position. Group I received 1.4 ml hyperbaric bupivacaine plus 12.5 µg neostigmine, Group II received 1.4 ml hyperbaric bupivacaine plus 25 µg neostigmine, Group III received 1.4 ml hyperbaric bupivacaine plus 50 µg neostigmine, Group IV (control) received 1.4 ml hyperbaric bupivacaine plus 0.1 ml saline. Tramadol was used for analgesia during postoperative period. Hemodynamic and respiratorial changes, time to first rescue analgesics, postoperative tramadol consumption, and advers effects were assessed. Neostigmine at these doses was found to have no effect on hemodynamic or respiratory parameters. The time first rescue analgesics were 273±47 minutes in GI, 595±47 minutes in GII, 869±49 minutes in GIII, 190±4 minutes in GIV. Postoperative tramadol consumtion in neostigmin groups was defined low in meaningful degree when compared to the control group. None of the patients in GIV had postoperative nausea-vomiting. Postoperative nausea-vomiting incidences were 8.3% (1 patient) in GI, 33.3% In this study it was concluded that intrathecal neostigmine produce a dose-dependent analgesia and dose-dependent incidence of adverse effects with doses studied. Neostigmine 12.5 µg dosage was enough for providing comfortable postoperative analgesia with low adverse effect.